ClinicalTrials.gg
RecruitingNCT07350395Updated Jan 20, 2026

Exploring and Measuring the Impact of Steroids in Children and Young People

An observational study in Rheumatic Diseases, Rheumatic Disorder and Rheumatologic Conditions (JRA,Lupus), sponsored by University of the West of England. Recruiting at 3 sites in United Kingdom. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by University of the West of England · Observational

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Study type
Observational
Model
Other
Time perspective
Other
Enrollment
70
Ages
Up to 18 Years
Sex
All
01

Study summary

Assessing the impact of glucocorticoids in children and young people with rheumatic conditions, to develop a patient reported outcome measure (PROM).

Glucocorticoids, also known as steroids, are a very effective medication for the treatment of rheumatological conditions. They are used to reduce inflammation, pain and damage to organs. However, steroids can have some unwanted side effects, such as, increased weight, skin changes, feeling anxious, delayed puberty, diabetes and loss of bone mass. These side effects can therefore impact children and young people's health related quality of life (HRQoL).

The investigators would like to create a new questionnaire for children and young people (CYP) who take steroids due to their rheumatological condition. The questionnaire, called a Patient Reported Outcome Measure, (PROM), will measure how steroids are affecting CYP. The first step in creating the questionnaire is to talk to children, young people and their parents/guardians about their experiences of taking steroids. The investigators plan to do this in focus groups, with people around the same age. The second step will then be to take everything people said in the focus group to create the questions in the questionnaire. Cognitive interviewing will then be used in a structured one on one interview to test for relevance, clarity and understanding of the questions.

Children, young people and their parents/guardians will be involved throughout the research. Children and young people will give their thoughts and feedback on resources created for participants (consent forms/assent forms/participation information sheet/interview schedule), as well as how the focus groups and cognitive interviews should be structured.

With consent, participants will be provided with a lay summary of the results. Results will also be published within peer-reviewed journals, special interest groups, trial meetings, patient charity meetings and presented at conferences.

02

Conditions studied

  • Rheumatic Diseases
  • Rheumatic Disorder
  • Rheumatologic Conditions (JRA,Lupus)

Browse trials for

Keywords

  • rheumatic diseases
  • children and young people
  • steroids
  • glucocorticoids
  • qualitative
03

In context

Rheumatic Diseases

264 studies on the registry are indexed under Rheumatic Diseases; 60 are open to participants now.

This study's planned enrollment of 70 is below the median of 225 across 90 observational studies indexed under Rheumatic Diseases.

Browse Rheumatic Diseases studies →

Lead sponsor

University of the West of England is the lead sponsor of 26 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Three NHS sites (paediatric rheumatology clinics) will be used for recruitment of participants:

Bristol Royal Hospital for Children Alder Hey Children's Hospital (Liverpool) Royal Hospital for Children (Glasgow)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Rheumatology patients aged 0 to18 years old. 2. Patients should have capacity to assent or consent immediately prior to the interview.

    3. The patient should have a good understanding of spoken and written English be able to understand the participant information sheets, assent/consent forms.

    4. Treatment with with intravenous or oral glucocorticoids for an or inflammatory condition within the previous two years (or longer duration).

Parents/guardians:

  1. Parents (mother/ father) or legal guardians of rheumatological patients fulfilling criteria 1-4 above.
  2. Parents or legal guardians should have capacity to consent for themselves (+/- their child) immediately prior to the interview.
  3. The parents or legal guardians should have a good understanding of spoken and written English be able to understand the participant information sheets, assent/consent forms.

Exclusion criteria

Exclusion Criteria:

  • 1. Rheumatology patients who are more than 18 years of age. 2. Patients who do not have capacity to assent or consent immediately prior to the interview.

    3. Patient who have insufficient understanding of spoken and written English be able to understand the participant information sheets, assent/consent forms.

    4. Patients who either have never taken or have not taken steroids within the last two years as part of their treatment plan for their rheumatological condition.

    5. Relative is not a parent or legal guardian. 6. Parents/guardians of rheumatology patients fulfilling any of the exclusion criteria above.

    7. Parents/guardians who do not have capacity to assent or consent immediately prior to the interview.

    8. Parents/guardians who have insufficient understanding of spoken and written English be able to understand the participant information sheets, assent/consent forms.

    9. Parents/guardians of rheumatology patients who have never taken steroids or have not taken steroids within the last two years as part of their treatment plan for their rheumatological condition.

    10. Membership of the steering committee

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
70 participants (estimated)
Patient registry
No

Groups and cohorts

  • Focus groups for parents with children under 8 years old
  • Focus groups with children 8-12 years old
  • Focus groups for young people aged 13-15 years old
  • Focus groups for young people aged 16-18 years old
  • Cognitive interviewing for parents with children under 8 years old
  • Cognitive interviewing for children 8-12 years old
  • Cognitive interviewing for young people aged 16-18 years old
  • Cognitive interviewing for young people aged 13-15 years old
06

What researchers measure

Primary outcomes

  1. To explore the impact of glucocorticoids (steroids) on health-related quality of life (HRQoL) in CYP.

    To develop a long list of potential questionnaire items for one or more patient reported outcome measures (PRO) for children and young people, who are treated with glucocorticoids, which assesses its impact of this treatment on their symptoms and everyday life.

    Time frame: Through study completion, an average of 1 year.

Secondary outcomes

  1. Secondary analysis of specific topics of greatest importance to patients and families may be performed based on anonymised qualitative dataset from objective 1

    Secondary analyses may in future also be used to explore specific topics of importance within the qualitative data, depending on what emerges as of greatest importance (e.g. impact on appearance, sense of self).

    Time frame: Through study completion, an average of 1 year.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — This is not a trial, it is an exploratory qualitative study, therefore outcome measures are not relevant.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2026, 11 months after the start.

Of 36 observational studies under Rheumatic Diseases, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 14. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Jan 20, 2026
StartActual
Nov 1, 2025
Primary completionEst.
Oct 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07350395
Lead sponsor
University of the West of England
Collaborators
Alder Hey Children's NHS Foundation Trust, Bristol Royal Hospital for Children, Royal Hospital for Sick Children
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Nov 1, 2025
Primary completion
Oct 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 20, 2026

Study contacts

Emily Barnes
Contact
emily4.barnes@live.uwe.ac.uk
+447747560680
Dr Jo Robson
Contact
jo.robson@uwe.ac.uk
+441173281973

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion